



ESTEVE's research activities again rated excellent by Profarma

ESTEVE's R&D&i activities have again been rated excellent by the Ministry of Industry's Profarma Plan. This new acknowledgment is already the 28th Seal of Quality awarded uninterruptedly to this Company —since Profarma's launching in 1986.

ESTEVE is classified in Group A of the 2013-2016 Profarma Plan, a group that includes genuinely innovative pharmaceutical companies conducting significant research with in-house pharmaceutical production or in-house basic or clinical R&D.

ESTEVE's constant bet on innovation has always been fundamental in the Company's philosophy, and 63 million euros were invested in R&D in 2014. Ten percent of a team of almost 2,300 professionals focuses exclusively on the research and development of new products.

The 2013-2016 Profarma Plan is a joint initiative of the Ministry of Industry, Energy and Tourism, of the Ministry of Economy and Competitiveness, and of the Ministry of Health, Social Services and Equality. The objective of this Plan is to improve the competitiveness of the pharmaceutical industry in Spain through sector modernization and by fostering activities that provide more added value —like research.